Matches in Wikidata for { <http://www.wikidata.org/entity/Q61975040> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- Q61975040 description "clinical trial" @default.
- Q61975040 description "ensayo clínico" @default.
- Q61975040 description "ensayu clínicu" @default.
- Q61975040 description "klinisch onderzoek" @default.
- Q61975040 description "клінічне випробування" @default.
- Q61975040 name "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma" @default.
- Q61975040 type Item @default.
- Q61975040 label "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma" @default.
- Q61975040 prefLabel "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma" @default.
- Q61975040 P1050 Q61975040-F6CB4EE6-3AE1-4BD5-B522-BA582999CEC1 @default.
- Q61975040 P1132 Q61975040-9613D64D-E72E-4249-A39C-0811C0A243D0 @default.
- Q61975040 P131 Q61975040-A61FCA9C-2CD2-4694-B19F-E0D781BAF50F @default.
- Q61975040 P1476 Q61975040-50AE3D8D-7B80-4D80-B81E-2C8DA42EFE21 @default.
- Q61975040 P17 Q61975040-17D28AA0-AD51-4B61-9834-A649332EC9E3 @default.
- Q61975040 P17 Q61975040-1EFCC097-4001-4BFA-96DB-54DB87C57546 @default.
- Q61975040 P17 Q61975040-283538B0-D4BE-412A-9BC0-93DE39917489 @default.
- Q61975040 P17 Q61975040-2D83D15B-07B2-4218-98BE-43BEB5575AB3 @default.
- Q61975040 P17 Q61975040-3A82D575-A662-4EE8-9308-14E6BA583784 @default.
- Q61975040 P17 Q61975040-569C9709-9AE3-4FA2-9841-626981A896C1 @default.
- Q61975040 P17 Q61975040-85BDB2D6-F628-4309-8255-E51AA8700E8F @default.
- Q61975040 P17 Q61975040-9F5A4A4E-4577-4655-923D-64733CC15865 @default.
- Q61975040 P17 Q61975040-C91D8897-BDE5-403E-933C-4DD574E130E3 @default.
- Q61975040 P17 Q61975040-DEC18BDB-1186-4D8D-8ED3-3399CB228350 @default.
- Q61975040 P17 Q61975040-E3037671-58B7-4422-8DFA-04FDC3F60741 @default.
- Q61975040 P17 Q61975040-E55D5F09-AD97-4ADE-965B-E0A01FE4405D @default.
- Q61975040 P17 Q61975040-E985DD1D-8C3D-4886-AF95-95D7D86D5F2E @default.
- Q61975040 P17 Q61975040-EEB2D7FD-5029-44EB-992D-691B1D285820 @default.
- Q61975040 P17 Q61975040-FAB21749-06AD-4A3C-86FA-C87DABF106EB @default.
- Q61975040 P2899 Q61975040-2A4884C7-6C3B-4BCD-BCCE-33CF61CFF3BA @default.
- Q61975040 P3098 Q61975040-15B43647-0150-4C61-9B7D-E3825633BA2E @default.
- Q61975040 P31 Q61975040-8528BAB6-3345-4641-A83D-CADEB0EA453D @default.
- Q61975040 P4844 Q61975040-0F251937-A7C7-4B0D-936A-3B577B91130D @default.
- Q61975040 P4844 Q61975040-4D86AA68-4476-4209-839A-C6B4BF55FBA6 @default.
- Q61975040 P4844 Q61975040-8D3A5F2F-D4E9-4D7E-A29D-4E4C252D9D19 @default.
- Q61975040 P4844 Q61975040-CC040D60-6265-474A-A626-E82498567289 @default.
- Q61975040 P4844 Q61975040-D400C819-A7BA-4CCB-BB07-D446E9355D2C @default.
- Q61975040 P4844 Q61975040-E7D94B13-B79A-4337-9401-354CC9300ED8 @default.
- Q61975040 P4844 Q61975040-FAB4BD64-D2F8-47F2-BBB2-566D6D18B2F1 @default.
- Q61975040 P580 Q61975040-10DFA105-DCDB-474A-A8E5-BC4EC2637981 @default.
- Q61975040 P582 Q61975040-B8ACD677-DE44-46EA-85D0-901CA40EF1D4 @default.
- Q61975040 P6099 Q61975040-9AD66756-AD1E-4DE8-800E-B3B55A53270D @default.
- Q61975040 P8363 Q61975040-17F61625-986C-4960-BA72-9885AC0C487C @default.
- Q61975040 P859 Q61975040-C99D8327-EF60-4510-989B-DA458C03DECD @default.
- Q61975040 P1050 Q208414 @default.
- Q61975040 P1132 "+403" @default.
- Q61975040 P131 Q1183 @default.
- Q61975040 P1476 "A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)" @default.
- Q61975040 P17 Q142 @default.
- Q61975040 P17 Q145 @default.
- Q61975040 P17 Q155 @default.
- Q61975040 P17 Q17 @default.
- Q61975040 P17 Q183 @default.
- Q61975040 P17 Q212 @default.
- Q61975040 P17 Q29 @default.
- Q61975040 P17 Q30 @default.
- Q61975040 P17 Q31 @default.
- Q61975040 P17 Q34 @default.
- Q61975040 P17 Q36 @default.
- Q61975040 P17 Q408 @default.
- Q61975040 P17 Q414 @default.
- Q61975040 P17 Q43 @default.
- Q61975040 P17 Q801 @default.
- Q61975040 P2899 "+18" @default.
- Q61975040 P3098 "NCT01974440" @default.
- Q61975040 P31 Q30612 @default.
- Q61975040 P4844 Q18936 @default.
- Q61975040 P4844 Q27272066 @default.
- Q61975040 P4844 Q29004943 @default.
- Q61975040 P4844 Q408524 @default.
- Q61975040 P4844 Q408977 @default.
- Q61975040 P4844 Q412323 @default.
- Q61975040 P4844 Q424972 @default.
- Q61975040 P580 "2014-01-31T00:00:00Z" @default.
- Q61975040 P582 "2020-07-15T00:00:00Z" @default.
- Q61975040 P6099 Q42824827 @default.
- Q61975040 P8363 Q78089383 @default.
- Q61975040 P859 Q903523 @default.